NanoString sales and marketing update

NanoString launched the nCounter Dx Analysis System for use in high-complexity, CLIA-certified, U.S. laboratories. The system runs the company's Prosigna Breast Cancer Prognostic Gene Signature Assay, which has 510(k) clearance in the U.S. for use as a prognostic indicator for distant recurrence-free survival at 10 years. The company expects Prosigna testing services to be available from qualified U.S. laboratories in 1Q14. ...